In 4.5 years, Punjab procured 43.44 crore pills of opioid used to treat drug addiction
Punjab has procured 43.44 crore Buprenorphine tablets for opioid substitution therapy in 4.5 years, with the annual requirement continuing to rise. The number of patients registered at Outpatient Opioid Assisted Treatment (OOAT) clinics has also increased from 2 lakh in 2…
Intelligence analysis by Llama
Punjab's de-addiction programme has seen a sharp rise in the procurement of Buprenorphine tablets, with the number of patients registered at OOAT clinics also increasing. However, the government has been questioned on whether the programme is reducing addiction or merely replacing one dependency with another.
Imagine you have a medicine that helps you stop taking bad drugs, but you have to take it every day for the rest of your life. That's what's happening in Punjab, where the government is giving out a lot of medicine to help people stop taking bad drugs. But some people are misusing the medicine, which is creating a new problem. The government needs to make sure that the medicine is being used correctly and that people are getting the help they need to stop taking bad drugs for good.
Analysis
Buprenorphine Procurement in Punjab: A Growing Concern
The Punjab government's de-addiction programme has been under scrutiny for its effectiveness in reducing addiction, and the recent rise in Buprenorphine tablet procurement has raised concerns about the programme's strategy and infrastructure. In just over four and a half years, Punjab has procured 43.44 crore Buprenorphine tablets for opioid substitution therapy, with the annual requirement continuing to rise. The number of patients registered at Outpatient Opioid Assisted Treatment (OOAT) clinics has also increased from 2 lakh in 2022 to 3.17 lakh in 2026.
The sharp rise in procurement has coincided with an increase in the number of patients registered at OOAT clinics, but the government has been questioned on whether the programme is reducing addiction or merely replacing one dependency with another. The Assembly committee has raised concerns about the misuse of Buprenorphine tablets, with some patients dissolving the tablets in water and injecting the solution intravenously, creating a fresh pattern of needle-based addiction.
The committee has also expressed concern over unregistered private de-addiction centres operating from residential buildings in districts, including Amritsar. Members asked how Buprenorphine tablets were reaching such centres when they lacked licences and qualified medical staff. The committee recommended an inquiry into illegal rehabilitation centres and possible diversion of substitution medicines.
The panel further sought details of Buprenorphine supplied to Punjab prisons during 2025, noting that jails house a large number of inmates booked under the NDPS Act and require strict monitoring of medicine distribution. Observing that medicines alone cannot ensure lasting recovery, the committee recommended strengthening counselling, rehabilitation and psychological support, besides constituting a joint medical and administrative team to evaluate the effectiveness of Punjab's de-addiction programme.
The government's success should ultimately be measured by the number of people who permanently quit drugs and successfully returned to normal life, rather than by the volume of medicines procured or patients registered. The committee's recommendations aim to address the concerns surrounding the de-addiction programme and ensure that the government's efforts are effective in reducing addiction and promoting recovery.
Key points
- Punjab has procured 43.44 crore Buprenorphine tablets for opioid substitution therapy in 4.5 years.
- The number of patients registered at Outpatient Opioid Assisted Treatment (OOAT) clinics has increased from 2 lakh in 2022 to 3.17 lakh in 2026.
- The government has been questioned on whether the de-addiction programme is reducing addiction or merely replacing one dependency with another.
- The Assembly committee has raised concerns about the misuse of Buprenorphine tablets and the lack of infrastructure in de-addiction centres.
- The committee has recommended strengthening counselling, rehabilitation and psychological support, and constituting a joint medical and administrative team to evaluate the effectiveness of the de-addiction programme.
If the government implements the committee's recommendations, it could lead to a more effective de-addiction programme that reduces addiction and promotes recovery. This could also lead to a decrease in the number of people misusing Buprenorphine tablets and an increase in the number of people successfully quitting drugs.
If the government does not address the concerns surrounding the de-addiction programme, it could lead to a rise in addiction and a decrease in the number of people successfully quitting drugs. This could also lead to a increase in the number of people misusing Buprenorphine tablets and a decrease in the effectiveness of the programme.
